Skip to main content
. 2021 Jan 6;39(6):652–662. doi: 10.1200/JCO.20.02333

FIG 3.

FIG 3.

CONSORT diagram. ADE, araC, daunorubicin, etoposide; CR1, first complete remission; KMT2Ar, KMT2A-rearranged; MAE, mitoxantrone, araC, etoposide; MRD, minimal residual disease.